Arix Bioscience plc, of London, appointed Jonathan Tobin managing director of its investment team. He will also join the boards of Arix portfolio companies Velosbio Inc. and Depixus SAS in addition to his current board positions at Artios Pharma Ltd., Atox Bio Inc., Stipe Therapeutics and Quench Bio Inc. Other changes to the investment team include: John Cassidy has been promoted to principal; Christian Schetter will join the board of Aura Biosciences Inc.; and Tim Xu will join the board of Optikira LLC and assume the role of board observer at Amplyx Pharmaceuticals Inc.
Cardurion Pharmaceuticals Inc., of Boston, appointed Peter S. Lawrence president and CEO.
Evelo Biosciences Inc., of Cambridge, Mass., appointed Neil Graham chief development officer.
Ico Therapeutics Inc., of Vancouver, British Columbia, appointed Kishor Wasan director of research.
MEI Pharma Inc., of San Diego, appointed Cheryl L. Cohen to its board.
Mersana Therapeutics Inc., of Cambridge, Mass., appointed Martin H. Huber to its board.
Moleculin Biotech Inc., of Houston, appointed Dominique Schols to its development team as a consultant.
Precision Biosciences Inc., of Durham, N.C., appointed Dora Alvarado senior vice president, human resources.
TCR2 Therapeutics Inc., of Cambridge, Mass., appointed Axel Hoos to its board.